323 related articles for article (PubMed ID: 25400636)
21. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.
Yoshio S; Kanto T; Kuroda S; Matsubara T; Higashitani K; Kakita N; Ishida H; Hiramatsu N; Nagano H; Sugiyama M; Murata K; Fukuhara T; Matsuura Y; Hayashi N; Mizokami M; Takehara T
Hepatology; 2013 May; 57(5):1705-15. PubMed ID: 23213063
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
23. The Role of Interferon-λ Locus Polymorphisms in Hepatitis C and Other Infectious Diseases.
Griffiths SJ; Dunnigan CM; Russell CD; Haas JG
J Innate Immun; 2015; 7(3):231-42. PubMed ID: 25634147
[TBL] [Abstract][Full Text] [Related]
24. Impairment of type I but not type III IFN signaling by hepatitis C virus infection influences antiviral responses in primary human hepatocytes.
Friborg J; Ross-Macdonald P; Cao J; Willard R; Lin B; Eggers B; McPhee F
PLoS One; 2015; 10(3):e0121734. PubMed ID: 25826356
[TBL] [Abstract][Full Text] [Related]
25. Activation of Type I and Type III Interferons in Chronic Hepatitis C.
Mihm S
J Innate Immun; 2015; 7(3):251-259. PubMed ID: 25766746
[TBL] [Abstract][Full Text] [Related]
26. Interferon-λ in the context of viral infections: production, response and therapeutic implications.
Hermant P; Michiels T
J Innate Immun; 2014; 6(5):563-74. PubMed ID: 24751921
[TBL] [Abstract][Full Text] [Related]
27. T-cell therapy for chronic viral hepatitis.
Bertoletti A; Tan AT; Koh S
Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.
Hamana A; Takahashi Y; Uchida T; Nishikawa M; Imamura M; Chayama K; Takakura Y
Antiviral Res; 2017 Oct; 146():130-138. PubMed ID: 28864074
[TBL] [Abstract][Full Text] [Related]
29. IFN-lambda therapy: current status and future perspectives.
Lasfar A; Zloza A; Cohen-Solal KA
Drug Discov Today; 2016 Jan; 21(1):167-171. PubMed ID: 26552337
[TBL] [Abstract][Full Text] [Related]
30. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
[TBL] [Abstract][Full Text] [Related]
31. What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?
O'Brien TR; Jackson SS
J Interferon Cytokine Res; 2019 Oct; 39(10):618-626. PubMed ID: 31161939
[TBL] [Abstract][Full Text] [Related]
32. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
[TBL] [Abstract][Full Text] [Related]
33. Distinct and overlapping genomic profiles and antiviral effects of Interferon-λ and -α on HCV-infected and noninfected hepatoma cells.
Kohli A; Zhang X; Yang J; Russell RS; Donnelly RP; Sheikh F; Sherman A; Young H; Imamichi T; Lempicki RA; Masur H; Kottilil S
J Viral Hepat; 2012 Dec; 19(12):843-53. PubMed ID: 23121362
[TBL] [Abstract][Full Text] [Related]
34. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.
Hopkins S; DiMassimo B; Rusnak P; Heuman D; Lalezari J; Sluder A; Scorneaux B; Mosier S; Kowalczyk P; Ribeill Y; Baugh J; Gallay P
J Hepatol; 2012 Jul; 57(1):47-54. PubMed ID: 22425702
[TBL] [Abstract][Full Text] [Related]
35. Safety, Tolerability, and Immunogenicity of Interferons.
Tovey MG; Lallemand C
Pharmaceuticals (Basel); 2010 Apr; 3(4):1162-1186. PubMed ID: 27713294
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?
Yang DR; Zhu HZ
World J Gastroenterol; 2015 Apr; 21(13):3786-800. PubMed ID: 25852264
[TBL] [Abstract][Full Text] [Related]
37. Prominent amphibian (Xenopus laevis) tadpole type III interferon response to the frog virus 3 ranavirus.
Grayfer L; De Jesús Andino F; Robert J
J Virol; 2015 May; 89(9):5072-82. PubMed ID: 25717104
[TBL] [Abstract][Full Text] [Related]
38. Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV).
Nakai M; Oshiumi H; Funami K; Okamoto M; Matsumoto M; Seya T; Sakamoto N
Sensors (Basel); 2015 Oct; 15(10):27160-73. PubMed ID: 26512676
[TBL] [Abstract][Full Text] [Related]
39. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections.
Egli A; Santer DM; O'Shea D; Tyrrell DL; Houghton M
Emerg Microbes Infect; 2014 Jul; 3(7):e51. PubMed ID: 26038748
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of type I and type III interferons in BNL hepatoma model.
Abushahba W; Balan M; Castaneda I; Yuan Y; Reuhl K; Raveche E; de la Torre A; Lasfar A; Kotenko SV
Cancer Immunol Immunother; 2010 Jul; 59(7):1059-71. PubMed ID: 20217081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
